Swinging at Lou Gehrig's disease, Peninsula drug maker strikes out

After spending "hundreds of millions" of dollars over eight years on an experimental drug for people with amyotrophic lateral sclerosis, or ALS, a South San Francisco company's late-stage trial came up short.

Source: bizjournals.com Health Care:Biotechnology headlines - November 21, 2017 Category: Biotechnology Authors: Ron Leuty Source Type: news